A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

Read about a medical student treated at MSK for aggressive cervical cancer who later returned to train alongside MSK surgeons.

Study Rundown: Cervical cancer is the fourth most common cancer affecting women worldwide. Previous trials have shown that adding pembrolizumab, an anti-PD1 antibody, to chemoradiotherapy may improve ...

Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient ...

Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs placebo plus chemotherapy in patients with early-stage non–small cell lung ...

As the KEYNOTE-A18 trial 10 furthers the application of pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer, it also prompts consideration for subsequent therapies in ...

Department of Gynecological Oncology and National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, ...

RAHWAY: Merck, also known as MSD outside the US and Canada, announced that the European Commission (EC) has approved two new indications for KEYTRUDA (pembrolizumab ... including five in gynecologic ...